Trials / Completed
CompletedNCT03619837
Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant
PRO-ACT: Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 122 (actual)
- Sponsor
- University of California, San Francisco · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
In this study, subjects that do not have Hepatitis C virus (HCV) will be transplanted with livers or kidneys from donors who do have HCV. Medications that are used to treat HCV will be given to the study subjects shortly after transplant to protect them from developing the problems HCV can cause to the liver.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sofosbuvir/Velpatasvir | Sofosbuvir/Velpatasvir starting early post-transplant for total of 12 weeks. |
| DRUG | Sofosbuvir/Velpatasvir/Voxilaprevir | Only for patients who fail initial treatment with Sofosbuvir/Velpatasvir. Dosage: 400mg/100mg/100mg daily for 12 weeks. |
Timeline
- Start date
- 2018-07-15
- Primary completion
- 2019-12-21
- Completion
- 2020-08-13
- First posted
- 2018-08-08
- Last updated
- 2021-03-03
- Results posted
- 2021-03-03
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03619837. Inclusion in this directory is not an endorsement.